Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF 40 Return-on-Tangible-Asset is 13.55% as of Mar. 2026, which is 1110% above its 10-year median of 1.12. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 679 Healthcare Providers & Services companies, NexgenRx ranks better than 67.01% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NexgenRx's annualizedNet Income for the quarter that ended in Mar. 2026 was $3.58 Mil. NexgenRx's average total tangible assets for the quarter that ended in Mar. 2026 was $26.41 Mil. Therefore, NexgenRx's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 13.55%.
The historical rank and industry rank for NexgenRx's Return-on-Tangible-Asset or its related term are showing as below:
NEGXF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.45 Med: 1.12 Max: 19.05
Current: 5.83
During the past 13 years, NexgenRx's highest Return-on-Tangible-Asset was 19.05%. The lowest was -7.45%. And the median was 1.12%.
NEGXF's Return-on-Tangible-Asset is ranked better than 67.01% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 2.51
vs NEGXF: 5.83
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
NexgenRx Return-on-Tangible-Asset Related Terms
NexgenRx Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for NexgenRx's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEGXF vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, NexgenRx's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where NexgenRx's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.55% mean?
NexgenRx (NEGXF) has a Return-on-Tangible-Asset of 13.55% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NexgenRx and its competitors. This is 1110% above median its historical median of 1.12. According to the industry distribution chart, NexgenRx ranks #224 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 33%.
Is NexgenRx's Return-on-Tangible-Asset too high?
NexgenRx's current Return-on-Tangible-Asset of 13.55% is 1110% above median its 10-year median of 1.12. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.51. NexgenRx's value of 13.55% is 439.8% above this industry median. Based on the distribution chart, NexgenRx ranks #224 out of 679 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #224 out of 679 companies for Return-on-Tangible-Asset. This puts NexgenRx in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.51. NexgenRx's value of 13.55% is 439.8% above this benchmark. While the company's 10-year median is 1.12 vs. the industry median of 2.51, NexgenRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current Return-on-Tangible-Asset of 13.55% is 439.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current Return-on-Tangible-Asset is 13.55%, which is 1110% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current Return-on-Tangible-Asset is 13.55%, which is 1110% above median its 10-year median of 1.12 and 439.8% above the Healthcare Providers & Services industry median of 2.51. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Return-on-Tangible-Asset is 13.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
Return-on-Tangible-Asset: 13.55% (1110% above median its 10-year median of 1.12)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 439.8% above the Healthcare Providers & Services median (#224 of 679)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score
Get the complete analysis for NEGXF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
